![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif)
| A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. IDEC-Y2B8 is a type of radiopharmaceutical. Also called Y 90 ibritumomab tiuxetan, Y 90 Zevalin, and yttrium Y 90 ibritumomab tiuxetan. |
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115195126im_/http://www.cancer.gov/images/spacer.gif) |